Eli Lilly Agrees to Acquire Safeguard Scientifics Partner Company Avid Radiopharmaceuticals
For the second time in as many weeks, I am pleased to announce that a major player in the pharmaceutical industry has recognized the value…
Posted by
Safeguard Insights
Partner Company Clarient (Nasdaq: CLRT) to be Acquired by GE Healthcare for $587 Million
At Safeguard Scientifics, our strategy is to provide growth capital for entrepreneurial and innovative life sciences and technology companies, build value in those companies and…
Posted by
Third Quarter 2010 Trends in Venture Capital
According to the latest MoneyTree survey conducted by PricewaterhouseCoopers and the National Venture Capital Association, venture capital investing in the third quarter of 2010 was…
Posted by
Advancements in Diagnostics
Advances in the life sciences will continue to have a far-reaching impact on virtually every aspect of our society. There is an abundance of companies…
Posted by
Video: James A. Datin Talks About Safeguard Scientifics’ Life Sciences Strategy
James A. Datin, Executive Vice President and Managing Director of Life Sciences Group at Safeguard Scientifics, discusses his thoughts on the opportunities in life sciences…
Posted by
Bloomberg Businessweek says Avid likely to Beat GE, Bayer to Market
On the eve of the International Conference on Alzheimer’s Disease (ICAD), Bloomberg Businessweek’s Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard…
Posted by
Diagnostic Imaging Continues to Garner Investor Interest
On the heels of the BIO International Convention, I came across this piece by FierceBiotech’s Maureen Martino highlighting a panel of biotech VCs who made…
Posted by
Avid Radiopharmaceuticals Announces Positive Interim Results from Phase III Clinical Trial of Amyloid Imaging Agent Florbetapir F18
Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…
Posted by
Avid Radiopharmaceuticals Making Strides Toward Clinical Trial Milestone
I frequently attribute Safeguard Scientifics’ success to our disciplined strategy built on five strategic themes, which we refer to as M2C3. We leverage these themes…
Posted by
